Spondyloarthritis & psoriatic arthritis
Comparative Effectiveness and Persistence of SB4 and Reference Etanercept in Patients With Psoriatic Arthritis in Norway
Authors' conclusion
At one year, outcomes for PsA disease activity and drug persistence were comparable for patients treated with either ETN or SB4. In patients undergoing a mandatory nonmedical switch from ETN to SB4, drug effectiveness was maintained during a two-year period.
Study context
- Population
- Patients with PsA naive to etanercept (ETN) treated with ETN or SB4 (1999–2021), Norwaymatched n = 144, both cohorts
- Participants
- 1,138 patients
- Exposure
- Reference etanercept vs biosimilar SB4
- ETNn = 644reference
- SB4n = 252
- Outcome
- Change from baseline in DAS28 and drug persistence
- Follow-up
- One year
Methodological detailspropensity-score matched, Kaplan-Meier analysis
- Propensity-score matched
- Kaplan-Meier analysis
Main finding
As reported in the abstract
Difference in change from baseline in DAS28, propensity score (PS)-matched
Between ETN and SB4Estimate (95% CI)
ETN (n = 54) and SB4 (n = 54)
difference in change from baseline 0.09(−0.33 to 0.50)
Difference in change from baseline in DAS28, PS-matched
mean difference (analysis of covariance) 0.01(−0.38 to 0.40)
Observational data: associations, not effects.
Further findings
| Outcome | Difference in change from baseline (95% CI) | |
|---|---|---|
| Difference in change from baseline in DAS28, unmatched · one yearETN (n = 140) and SB4 (n = 132) · in favor of ETN | 0.67 (0.38–0.96) | |
| −0.500.51Difference (linear scale) |
Mean
| Outcome | ETN | SB4 | HR (95% CI) | |
|---|---|---|---|---|
| Drug persistence, unmatched · one year | 0.75 (95% CI 0.71–0.78) | 0.58 (95% CI 0.51–0.63) | 2.45 (2.02–2.97) | |
| Drug persistence, PS-matched · one year | 0.55 (95% CI 0.46–0.63) | 0.60 (95% CI 0.51–0.67) | 1.29 (0.94–1.76) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Comparative Effectiveness and Persistence of SB4 and Reference Etanercept in Patients With Psoriatic Arthritis in Norway. Arthritis Care Res (Hoboken). Published 29 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →